Disseminated on behalf of: MustGrow Biologics Corp.
Colin Bletsky, Chief Operating Officer of MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FRA: 0C0), discusses the biotech innovator’s focus on replacing synthetic soil fumigants with mustard seed-derived biocontrol. Operating from Saskatchewan and registering in North America and licensing to Bayer into Europe, the Middle East and Africa, MustGrow’s goal is to give growers of high-value fruit and vegetable crops an effective, naturally derived alternative — a position that strengthens as regulators withdraw legacy chemistries and demand for sustainable crop inputs accelerates.
TerraMG™ technology: What differentiates MustGrow’s biocontrol platform
Unlike peers building microbial products, TerraMG™ works from a compound occurring naturally in mustard seed, protected by approximately 110 issued and pending patents. Its lead soil biocontrol, TerraMG™, is applied before planting to treat soil-borne nematodes and disease, then breaks down without persistent residue. According to Bletsky, “Bayer is a global leader in crop science, and this payment marks another significant validation for our mustard-based biocontrol technology, TerraMG.” Because the active ingredient is derived from an agricultural food grade crop rather than synthesized, the approach could ease regulatory friction and fits both organic and conventional programs.
Biocontrol market opportunity: A $17 billion runway to 2030
With fumigant bans and pest resistance reshaping the crop protection landscape, MustGrow is strategically positioned to capture emerging demand. The Business Research Company estimates the global biocontrol market at USD $8.12 billion in 2025, reaching USD $17.27 billion by 2030 — a 16.2% compound annual growth rate. Rather than fund a global sales force, MustGrow’s strategy is to license its technology to established partners and holds costs down, aiming to provide investors with early-stage, leveraged exposure to biologicals adoption through royalties and manufacturing sales carried on a partner’s distribution network.
Bayer milestone payment marks progress under the EMEA license
Recent milestones include MustGrow’s first milestone payment from Bayer under their License and Collaboration Agreement, which gives Bayer access to the company’s mustard-based biocontrol technologies for soil applications across Europe, the Middle East and Africa. Bletsky says, “The upfront payment, milestone payments, and development work Bayer is responsible for can total approximately $35 to $40 million US dollars over the next several years.” That figure is before royalties or manufacturing sales. Bayer carries the regulatory and commercialization workload in its territory.
Additional milestones and the path to commercial sales
As MustGrow advances from technical validation toward revenue, it sits at the intersection of tightening pesticide regulation and grower demand for effective alternatives. With a tier-one partner funding the route to market, the company is positioned to deliver disciplined, milestone-driven progress. Learn more at mustgrow.ca.
Transcript
Colin Bletsky: MustGrow Biologics is pleased to announce we’ve received our first milestone payment from Bayer under our License and Collaboration Agreement.
This is a meaningful moment for MustGrow. Bayer is a global leader in crop science, and this payment marks another significant validation for our mustard-based biocontrol technology, TerraMG™.
This agreement gives Bayer the access to our mustard-based biocontrol technologies for soil applications across Europe, the Middle East, and Africa. The upfront payment, milestone payments, and development work Bayer is responsible for can total approximately $35 to $40 million US dollars over the next several years. That’s before any royalties or manufacturing sales.
This first milestone was tied to technical product development targets, and Bayer continues to advance regulatory and commercialization work in their territory. Follow our updates as we watch for additional milestones and move closer to commercial sales.
About MustGrow Biologics Corp.
MustGrow Biologics is a Saskatchewan-based agriculture biotechnology company commercializing mustard seed-derived biological solutions — including TerraMG™ soil biocontrol and TerraSante™ biofertility — backed by approximately 110 issued and pending patents. The company pursues a capital-efficient licensing model, partnering with global crop science leaders such as Bayer, which holds exclusive rights across Europe, the Middle East and Africa under an agreement valued at approximately USD $35–40 million before royalties and manufacturing sales.
To learn more about MustGrow Biologics, visit their website here. For the latest updates, follow the company on Facebook, LinkedIn, X, and YouTube.
